SMOOTH.
NATURAL-LOOKING.
LONG-LASTING.1-13

Results with the JUVÉDERM® Collection of Fillers

Actual patients. Results may vary. 

THE #1 CHOSEN14,*, REQUESTED15,†, AND RECOMMENDED
FILLER BRAND

by patients16,‡ and providers17,§

98%

JUVÉDERM® is trusted
by patients

98% of patients say JUVÉDERM® is a brand they trust18

In a March 2024 survey of patients (n = 100) who have been treated with one or more JUVÉDERM® products in the past 2 years.18

9/10

JUVÉDERM® is trusted
by injectors

9 out of 10 injectors would choose from the JUVÉDERM® Collection when selecting a filler for themselves or a loved one.19

In a January 2024 survey of HCPs (n = 100) with experience using 2+ dermal filler brands, including JUVÉDERM®.19

2X MORE

JUVÉDERM® is the preferred filler option among HCPs

2X more HCPs preferred the JUVÉDERM® brand
over other dermal filler brands20

In a July 2022 survey of HCPs (n = 354) with experience using 3+ dermal filler brands, including JUVÉDERM®.20

10 FDA APPROVALS.
6 PRODUCTS.
1 COLLECTION.1-16.

Specifically designed to customize your patient's JUVÉDERM® Journey1-6

Find out more

Actual patient. Results may vary.

THE JUVÉDERM® ERGONOMIC SYRINGE FIT AND FEEL IS DESIGNED FOR YOUR COMFORT

JUVÉDERM® is the only collection of fillers that uses a certified ergonomic syringe designed for improved injector control23

Learn more

A COLLECTION
OF FIRSTS.

Since 2006, JUVÉDERM® has been a leader in HA dermal filler innovation.

JUVÉDERM® ULTRA

JUVÉDERM® ULTRA PLUS

The first HA dermal fillers FDA approved for facial wrinkles and folds utilizing a homogenized manufacturing process4, 6, 24

2006

JUVÉDERM® ULTRA

JUVÉDERM® ULTRA PLUS

The first use of lidocaine in an HA dermal filler4, 6, 25

2010

JUVÉDERM® VOLUMA® XC

The first HA dermal filler FDA approved for the midface1, 26

2013

logo

The first certified ergonomic syringe23

2018

JUVÉDERM® VOLUMA® XC

The first HA dermal filler FDA approved for the chin1, 27

2020

JUVÉDERM® VOLBELLA® XC

The first HA dermal filler FDA approved for infraorbital hollows5, 28

2021

JUVÉDERM® VOLUX® XC

The first HA dermal filler FDA approved for immediate and long-lasting jawline definition—results last up to 1 year*2, 29

2022

*With optimal treatment

EXPLORE

NEW TO ALLERGAN AESTHETICS?

Contact Allergan Aesthetics at 1-844-NEW-2AGN to set up your account.

EXISTING PRACTITIONERS

Purchase products, pay bills, and access detailed reports at your convenience.

Access Allergan Direct Resources

Allē

Learn how Allē, the industry-leading consumer loyalty program, serves your patients.

Explore Allē Resources

Actual patient. Results may vary.

alle logo

* Based on January 2024 healthcare provider survey data (n = 886).14

† Based on a November 2022 survey of females recruited from market research panels who have had filler treatment in the past 2 years (n = 98).15

‡ Among leading filler brands in survey data collected January to April 2023, 70% of females treated with a JUVÉDERM® filler in the last year were likely to recommend it to friends interested in dermal fillers (n = 356).16

§ Among leading brands in survey data collected February to April 2023, 64% of healthcare providers who use JUVÉDERM® fillers in their practice are likely to recommend it to colleagues (n = 747).17

References: 1. JUVÉDERM® VOLUMA® XC Directions for Use, June 2024. 2. JUVÉDERM® VOLUX™ XC Directions for Use, May 2023. 3. JUVÉDERM®  VOLLURE™ XC Directions for Use, May 2023. 4. JUVÉDERM® Ultra Plus XC Directions for Use, May 2023. 5. JUVÉDERM® VOLBELLA® XC Directions for Use, May 2023. 6. JUVÉDERM® Ultra XC Directions for Use, May 2023. 7. Data on file, Allergan, October 11, 2018; CSR JUVÉDERM®  VOLUMA™ XC-006. 8. Data on file, Allergan, August 31, 2012; Interim 24-Month Study Report: JUVÉDERM® VOLUMA™ XC-002. 9. Data on file, Allergan, May 29, 2015; CSR JUVÉDERM® VOLBELLA™ XC-004 Final Report. 10. Data on file, Allergan, August 21, 2019; JUVÉDERM® VOLBELLA™ XC CSR 1932-701-008. 11. Data on file, Allergan, October 26, 2015; CSR JUVÉDERM® VOLLURE™ XC S17L-001 Final Report. 12. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST®  Nasolabial Fold Study Group. JUVÉDERM®  injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008;28(1):17-23. 13. Data on file, Allergan, January 26, 2021; Clinical Study Report V25L-002. 14. Data on file, Allergan Aesthetics, January 2024; Dermal Filler Aesthetic Monthly Tracker. 15. Data on file, Allergan, February 14, 2023; Filler Consumer A&U. 16. Data on file, Allergan, April 2023; Dermal Filler NPS from Consumer Aesthetic Tracker. 17. Data on file, Allergan, April 2023; Net Promoter Score: HCP Perceptions for Dermal Filler Brands (Q1 2023). 18. Data on file, Allergan, March 2024; JUVÉDERM Consumer Claims Quick Quant. 19. Data on file, Allergan, January 2024; JUVÉDERM HCP Claims Quick Quant. 20. Data on file, Allergan, July 2022; Corporate Image Report. 21. Monheit G, Beer K, Hardas B, et al. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds: results of a randomized, controlled study. Dermatol Surg. 2018;44:670-678. 22. de la Guardia C, Virno A, Musumeci M, Bernardin A, Silberberg MB. Rheologic and physicochemical characteristics of hyaluronic acid fillers: overview and relationship to product performance. Facial Plast Surg. 2022;38(2):116-123.23. Data on file, Allergan, August 9, 2018; United States Ergonomics JUVÉDERM® Syringe Certification. 24. US Department of Health and Human Services. JUVÉDERM® 24HV, JUVÉDERM® 30 and JUVÉDERM® 30HV gel implants—P050047 approval letter. US Food and Drug Administration. Published June 2, 2006. Accessed November 25, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047A.pdf. 25. US Department of Health and Human Services. JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC—P050047/S005 approval letter. US Food and Drug Administration. Published January 7, 2010. Accessed March 20, 2024.
https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047S005A.pdf. 26. US Department of Health and Human Services. JUVÉDERM® VOLUMA XC—P110033 approval letter. US Food and Drug Administration. Published October 22, 2013. Accessed March 20, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033A.pdf. 27. FDA approves JUVÉDERM® VOLUMA XC for enhancement of the chin region. News release. Allergan Aesthetics, an AbbVie company; June 15, 2020. Accessed March 20, 2024. https://news.abbvie.com/2020-06-15-FDA-Approves-JUVEDERM-R-VOLUMA-TM-XC-for-Enhancement-of-the-Chin-Region. 28. FDA approves JUVÉDERM® VOLBELLA® XC for undereye hollows. News release. Allergan Aesthetics, an AbbVie company. Published February 8, 2022. Accessed March 20, 2024. https://news.abbvie.com/2022-02-08-FDA-Approves-JUVEDERM-R-VOLBELLA-R-XC-For-Undereye-Hollows. 29. FDA approves JUVÉDERM® VOLUX XC for improvement of jawline definition. News release. Allergan Aesthetics, an AbbVie company. Published August 3, 2022. Accessed March 20, 2024. https://news.abbvie.com/2022-08-03-FDA-Approves-JUVEDERM-R-VOLUX-TM-XC-for-Improvement-of-Jawline-Definition.

IMPORTANT SAFETY INFORMATION & APPROVED USES

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

APPROVED USES JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss, for augmentation of the chin region to improve the chin profile, and for augmentation of the temple region to improve moderate to severe temple hollowing in adults over 21...

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

INDICATIONS

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face, for augmentation of the chin region to improve the chin profile, and for supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21.

JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.

JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

JUVÉDERM® Collection of Fillers Indications and Important Safety Information

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products

WARNINGS

  • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

ADVERSE EVENTS

The most common reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support at 1-877-345-5372. Please visit rxabbvie.com for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

PRECAUTIONS

  • To minimize the risk of potential complications, these products should only be used by healthcare professionals who are knowledgeable about the anatomy and the product(s) for use in indicated area(s), and who have appropriate training in facial anatomy, vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
  • The potential risks of soft tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
  • The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
  • The safety for use of these products in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
  • The safety for use during pregnancy and in breastfeeding females has not been established
  • The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation, 22 and 80 years of age for chin augmentation, and 32 and 82 years of age for improvement of temple hollowing
  • The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and the safety for use of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC, and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
  • Dermal filler implantation carries a risk of infection. Follow standard precautions
  • Dermal fillers should be used with caution in patients on immunosuppressive therapy
  • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
  • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
  • The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
  • The safety of using a cannula with JUVÉDERM® VOLUMA® XC for cheek augmentation in patients with Fitzpatrick Skin Types V and VI or to improve temple hollowing has not been established
  • JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
  • Patients may experience late-onset adverse events with injectable gel implants, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
  • Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lb) body mass per year. The safety of injecting greater amounts has not been established
  • Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied

AbbVie may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, “cookies”). We use this data for multiple purposes, including for online targeted advertising (advertisements...